Article
Oncology
S. Novello, V Torri, C. Grohe, S. Kurz, M. Serke, T. Wehler, A. Meyer, D. Ladage, M. Geissler, I Colantonio, C. Cauchi, E. Stoelben, A. Ceribelli, C. Kropf-Sanchen, G. Valmadre, G. Borra, M. Schena, A. Morabito, A. Santo, V Gregorc, R. Chiari, M. Reck, G. Schmid-Bindert, G. Folprecht, F. Griesinger, A. Follador, P. Pedrazzoli, A. Bearz, O. Caffo, N. J. Dickgreber, L. Irtelli, G. Wiest, V Monica, L. Porcu, C. Manegold, G. Scagliotti
Summary: This study aimed to evaluate the predictive utility of ERCC1 and TS mRNA expression levels in resected tumors. The results showed that tailored adjuvant chemotherapy in completely resected stage II-III NSCLC demonstrated a non-statistically significant trend for overall survival favoring the tailored arm, with better efficacy/toxicity ratio compared to standard chemotherapy.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Roy S. Herbst, Yi-Long Wu, Thomas John, Christian Grohe, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, Konstantin Laktionov, Sang-We Kim, Chong-Jen Yu, Huu Vinh Vu, Shun Lu, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi
Summary: The study demonstrates that adjuvant osimertinib provides a prolonged disease-free survival (DFS) benefit, reduces the risk of recurrence, improves central nervous system (CNS) DFS, and has a consistent safety profile in resected EGFR-mutated NSCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola, Minna Tanner, Johan Ahlgren, Paivi Auvinen, Outi Lahdenpera, Kenneth Villman, Paul Nyandoto, Greger Nilsson, Paula Poikonen-Saksela, Vesa Kataja, Petri Bono, Jouni Junnila, Henrik Lindman
Summary: The study suggests that adding capecitabine to a chemotherapy regimen containing docetaxel, epirubicin, and cyclophosphamide can prolong the survival of patients with early breast cancer. Data shows that patients in the TX-CEX group had longer survival compared to those in the T-CEF group, especially for patients with estrogen receptor-negative and triple-negative cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni
Summary: In this randomized, open-label trial, adjuvant nab-paclitaxel + gemcitabine was compared with gemcitabine alone for resected pancreatic ductal adenocarcinoma. The study found that although nab-paclitaxel + gemcitabine showed favorable overall survival, it did not meet the primary endpoint of independently assessed disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
James Isaacs, Thomas E. Stinchcombe
Summary: Approximately one-third of NSCLC patients can undergo surgical resection. Neoadjuvant and adjuvant chemotherapy have been shown to improve survival outcomes. Recent trials have explored immunotherapy and targeted therapy in early-stage patients, showing improved disease-free survival.
Article
Oncology
Danhui Weng, Huihua Xiong, Changkun Zhu, Xiaoyun Wan, Yaxia Chen, Xinyu Wang, Youzhong Zhang, Jie Jiang, Xi Zhang, Qinglei Gao, Gang Chen, Hui Xing, Changyu Wang, Kezhen Li, Yaheng Chen, Yuyan Mao, Dongxiao Hu, Zimin Pan, Qingqin Chen, Baoxia Cui, Kun Song, Cunjian Yi, Guangcai Peng, Xiaobing Han, Ruifang An, Liangsheng Fan, Wei Wang, Tingchuan Xiong, Yile Chen, Zhenzi Tang, Lin Li, Xingsheng Yang, Xiaodong Cheng, Weiguo Lu, Hui Wang, Beihua Kong, Xing Xie, Ding Ma
Summary: This study assessed the non-inferiority of adjuvant chemotherapy alone versus adjuvant concurrent chemoradiotherapy as an alternative strategy for patients with early-stage cervical cancer. The results showed that adjuvant chemotherapy alone had similar efficacy in terms of prognosis, adverse effects, and quality of life compared to adjuvant concurrent chemoradiotherapy.
FRONTIERS OF MEDICINE
(2023)
Article
Oncology
Mary O'Brien, Luis Paz-Ares, Sandrine Marreaud, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martinez-Marti, Martin Faehling, Masahiro Tsuboi, Jong-Seok Lee, Kazuhiko Nakagawa, Jing Yang, Ayman Samkari, Steven M. Keller, Murielle Mauer, Nitish Jha, Rolf Stahel, Benjamin Besse, Solange Peters
Summary: This study evaluated the use of Pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC. The results showed that Pembrolizumab significantly improved disease-free survival in both the overall population and the PD-L1 TPS of 50% or greater population.
Article
Oncology
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Elisabeth Quoix, Julien Mazieres, Denis Moro-Sibilot, Eric Dansin, Olivier Molinier, Hugues Morel, Eric Pichon, Alexis Cortot, Josiane Otto, Francois Chomy, Pierre-Jean Souquet, Nicolas Cloarec, Etienne Giroux-Leprieur, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Valery Attignon, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Filippo Gustavo Dall'Olio, Marta Jimenez, Jean-Charles Soria, Benjamin Besse
Summary: Targeted therapies and immune checkpoint blockers have revolutionized the treatment of non-small cell lung cancer. This study investigated the use of targeted therapies and immune checkpoint blockers as maintenance therapy based on molecular characterization. The results showed no significant differences in progression-free survival between targeted therapies and standard-of-care, and immune checkpoint blockers showed enhanced benefits in patients with PD-L1 >= 1%.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Wen-Fang Tang, Hong-Yu Ye, Xuan Tang, Jian-Wei Su, Kang-Mei Xu, Wen-Zhao Zhong, Yi Liang
Summary: Chemotherapy is currently the standard adjuvant treatment for early-stage non-small cell lung cancer (NSCLC), but its effectiveness in improving 5-year survival rates is limited. Immunotherapy using immune checkpoint inhibitors (ICIs) has shown great potential in treating advanced NSCLC, and there is growing interest in its role in early-stage NSCLC. This article summarizes the rationale for adjuvant immunotherapy, ongoing clinical trials, and challenges in the field, and emphasizes the need for further research and validation of the role of adjuvant immunotherapy in early-stage NSCLC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
John Kirkwood, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M. Meniawy, Paolo A. Ascierto, Alexander M. Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V. Long
Summary: Nivolumab is an effective and well-tolerated adjuvant treatment for patients with resected stage IIB/C melanoma.
Article
Oncology
Norihito Okumura, Junichi Soh, Hiroyuki Suzuki, Masao Nakata, Toshiya Fujiwara, Hiroshige Nakamura, Makoto Sonobe, Takuji Fujinaga, Kazuhiko Kataoka, Kenichi Gemba, Masafumi Kataoka, Katsuyuki Hotta, Hiroshige Yoshioka, Keitaro Matsuo, Junichi Sakamoto, Hiroshi Date, Shinichi Toyooka
Summary: The alternate-day oral administration of S-1 for 1 year as adjuvant chemotherapy in completely resected stage I NSCLC was shown to be feasible with low toxicity, demonstrating potential therapeutic benefits.
Article
Oncology
Di Li, Chaoqiang Deng, Qiang Zheng, Fangqiu Fu, Shengping Wang, Yuan Li, Haiquan Chen, Yang Zhang
Summary: Adjuvant chemotherapy shows survival benefit for patients without pathologic lymph node metastasis, while adjuvant chemoradiotherapy may achieve a significant survival benefit for patients with pathologic lymph node metastasis. Further prospective studies are needed to validate the results.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Enriqueta Felip, Nasser Altorki, Caicun Zhou, Tibor Csoszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, Andrey Akopov, Alex Martinez-Marti, Hirotsugu Kenmotsu, Yuh-Min Chen, Antonio Chella, Shunichi Sugawara, David Voong, Fan Wu, Jing Yi, Yu Deng, Mark McCleland, Elizabeth Bennett, Barbara Gitlitz, Heather Wakelee
Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.
Article
Oncology
Wenjie Ni, Shufei Yu, Zefen Xiao, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Jun Liang, Jima Lv, Shugeng Gao, Yousheng Mao, Qi Xue, Kelin Sun, Xiangyang Liu, Dekang Fang, Jian Li, Dali Wang, Jun Zhao, Yushun Gao
Summary: The study demonstrated that postoperative radiotherapy/postoperative concurrent chemoradiotherapy (PORT/POCRT) could significantly improve disease-free survival and overall survival in patients with stage IIB-III esophageal squamous cell carcinoma.